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Abstract
Background: Bacterial sepsis is a major threat in neonates born prematurely, and is associated with elevated morbidity and
mortality. Little is known on the innate immune response to bacteria among extremely premature infants.
Methodology/Principal Findings: We compared innate immune functions to bacteria commonly causing sepsis in 21
infants of less than 28 wks of gestational age, 24 infants born between 28 and 32 wks of gestational age, 25 term newborns
and 20 healthy adults. Levels of surface expression of innate immune receptors (CD14, TLR2, TLR4, and MD-2) for Gram-
positive and Gram-negative bacteria were measured in cord blood leukocytes at the time of birth. The cytokine response to
bacteria of those leukocytes as well as plasma-dependent opsonophagocytosis of bacteria by target leukocytes was also
measured in the presence or absence of interferon-c. Leukocytes from extremely premature infants expressed very low
levels of receptors important for bacterial recognition. Leukocyte inflammatory responses to bacteria and opsonophago-
cytic activity of plasma from premature infants were also severely impaired compared to term newborns or adults. These
innate immune defects could be corrected when blood from premature infants was incubated ex vivo 12 hrs with
interferon-c.
Conclusion/Significance: Premature infants display markedly impaired innate immune functions, which likely account for
their propensity to develop bacterial sepsis during the neonatal period. The fetal innate immune response progressively
matures in the last three months in utero. Ex vivo treatment of leukocytes from premature neonates with interferon-c
reversed their innate immune responses deficiency to bacteria. These data represent a promising proof-of-concept to treat
premature newborns at the time of delivery with pharmacological agents aimed at maturing innate immune responses in
order to prevent neonatal sepsis.
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Introduction
Twenty percent of premature infants surviving beyond the first
three days of life will develop one or more culture-proven
bacteraemic sepsis. As much as 46% of infants born before 25
weeks of gestational age will develop sepsis [1]. Coagulase-negative
staphylococci, mainly S.epidermidis, are responsible for half of all
sepsis, and the rest is caused by other Gram-positive bacteria and
Gram-negative bacteria such as E.coli [1,2]. The prevalence of
neonatal sepsis is inversely correlated with gestational age and
birth weight, and is associated with morbid complications such as
bronchopulmonary dysplasia, cerebral palsy, an increased hospital
length of stay, and a high mortality rate [1,3]. Whereas sepsis
secondary to coagulase-negative staphylococci, is rarely fatal,
neonatal sepsis due to Gram-negative bacteria is associated with
an elevated mortality [2].
The innate immune system is essential for the newborn’s
defence against microorganisms during the first months of life.
Adaptive immunity is still immature, and immunological memory
only starts to develop. In neonates, innate immune defences
against bacteria rely on soluble proteins (mainly opsonins,
complement and maternal immunoglobulins) and phagocytes such
as neutrophils. Hypogammaglobulinemia and low complement
activity have been reported in premature infants and may play a
role in their impaired immunity against bacteria. When measured,
levels of opsonins such as collectins were found to be low in
premature infants [4,5].
The recognition of the presence of bacteria as nonself and
dangerous intruders is complex and involves an array of receptors
present at the surface of host leukocytes, mainly phagocytes. The
main receptors involved in this process are Toll-like receptors
(TLRs) and associated molecules. TLRs recognize and bind
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from Gram negative bacteria (TLR4/MD-2 complex) and
lipopeptides from Gram-positive and Gram-negative bacteria
(TLR2) [6]. CD14 is a pattern recognition receptor binding and
transferring various bacterial molecules to TLRs [7]. TLRs start to
be expressed in foetal tissues as early as during the 18–21 weeks of
gestational age [8]. Monocyte TLR4 and CD14 expression levels
were found to be lower in premature neonates as compared to
term newborns and adults [9,10,11]. The TLR4-associated
molecule MD-2, essential for LPS recognition and binding, was
found in term infants and adult Paneth cells but not in premature
neonates [12]. We hypothesized that the increased prevalence of
neonatal sepsis in extremely premature infants was associated with
an immaturity of their innate immune system. We measured the
expression of receptors of the innate immunity in leukocytes from
cord blood in premature neonates, tested their response to bacteria
and the capacity of their plasma to enhance bacterial phagocytosis.
We finally tested if a short ex vivo treatment with interferon-c could
boost innate immune functions of premature neonate leukocytes.
Results
Characteristics of patients
Ninety subjects were included. Characteristics of the 70 infants
(21 extremely low birth weight, ELBW, infants of less than 28 wks
of gestational age; 24 very low birth weight, VLBW, infants born
between 28 and 32 wks of gestational age; and 25 term newborn)
are shown in Table 1. Gestational age, birth weight, Apgar score
at 5 minutes, and frequency of caesarean delivery were statistically
different between infant groups, whereas mother age, maternal
diabetes, prolonged rupture of the membranes were not
statistically different. Although not different between ELBW and
VLBW infants, maternal pre-eclampsia was statistically more
frequent in premature than in term newborn. White blood cell
count was not statistically different between ELBW and VLBW
infants, but was lower in both groups when compared with term
newborns (P,0.001). The adult control group (n=20) median age
was 32 yrs (interquartile range, IQR: 28.7–36.2 yr.), and mal-
e:female ratio was 12:8.
Premature infants have a low leukocyte surface
expression of TLR2, TLR4, CD14 AND MD-2
Receptor surface expression was assessed in 80 subjects after
gating subpopulations of circulating leukocytes (Figure 1A, and
1B). Neutrophils from ELBW newborns had a significantly
reduced TLR2, TLR4, CD14 and MD-2 surface expression when
compared to adults. Whereas surface expression of MD-2, CD14
and TLR2 significantly increased with gestational age, TLR4
expression was found to be similar in premature and term
newborns. Only TLR2, TLR4, and CD14, but not MD-2
expression, was found to be lower in term newborn neutrophils
as compared with control adults. CD16 surface expression was
lower in neutrophils from all infants compared to adults.
Monocyte HLA-DR expression was not statistically different
between groups. Monocytes TLR4 expression was found to be
lower only in ELBW infants. Monocyte TLR4 expression levels
were not statistically different between VLBW, term newborns and
control adults. Monocyte expression of MD-2, CD14 and TLR2
were lower in both ELBW and VLBW infants as compared to
Table 1. Baseline Characteristics and outcome of newborns.
ELBW VLBW Term Newborn
N=21 N=24 N=25
Gestational age – weeks 26 [24–27] 31 [29–32] 39 [38–41]
Weight – grams 705 [600–850] 1495 [1135–1763] 3310 [2970–3650]
Male gender no. (%) 9 (42.8) 12 (50) 13 (52)
Apgar score at 5 min 7 [2–8] 8 [7–9] 10 [10–10]
WBC count at delivery (G/L) 9.2 [6.0–12.7] 9.8 [6.6–12.8] 17.5 [15.7–25.9] {
Neutrophils count (G/L) 5.3 [2.1–6.2] 3.7 [2.5–5.9] 11.4 [9.3–16.5] {
Lymphocytes count (G/L) 3.3 [2.3–4.2] 4.5 [2.4–5.9] 4.6 [3.3–6.4] {
Monocytes count (G/L) 0.7[0.4–1.1 ] 0.8 [0.5–1.2] 2.4 [1.5–5.7] {
Cesarean delivery no.(%) 9 (42.8) 18 (75) 2 (8)
Duration of Hospital Stay – days 1 [1–58] 30 [8–47] 2[1–3]
Mother age – years 33 [27–35] 32 [30–34] 31 [28–35.2]
Maternal pre-eclampsia 5 (23.8) 7 (21.2) 0 (0)
Maternal diabetes 2 (9.5) 0 (0) 0 (0)
Rupture of the membranes for .24 hrs 2 (9.5) 4 (16.6) 6 (24)
Late onset sepsis 4 (19) 1 (4.1) 0 (0)
Early onset sepsis 0 (0) 1 (4.1) 0 (0)
IVH grade 4 3 (14.3) 1 (4.1) 0 (0)
Death 14 (66.7) 2 (8.3) 0 (0)
Continuous data are expressed as median and interquartile range [IQR] and categorical data as number (%).
ELBW, extremely low birth weight born before 28 wks of gestational age; VLBW, very low birth weight born between 28 and 32 wks of gestational age, WBC, white
blood cell; IVH, intraventricular haemorrhage. {, WBC count was performed in term newborn if there was an infectious risk at delivery (WBC count performed in ELBW,
N=13; VLBW, N=24; and in term newborns, N=8). Four premature infants (ELBW, N=3; VLBW, N=1) did not receive pulmonary maturation with antenatal
corticosteroid therapy.
doi:10.1371/journal.pone.0032863.t001
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TLR2, TLR4 and MD-2 surface expression was found between
term newborns and adults (Figure 1B).
We next investigated whether a low surface MD-2 expression
observed in premature phagocytes could be balanced by an
increased level of the soluble form of MD-2 (sMD-2) in plasma
from 80 subjects. LPS/sMD-2-dependent activation of TLR4-
expressing cells was found to be similar in all groups tested
(Figure 1C), suggesting that - at basal level - no significant sMD-2
activity was detected in premature infants, term newborns, and
adults.
Defective opsonophagocytosis in premature infants
We used the well-behaved and consistent DMSO-differentiated
HL-60 cells as a surrogate neutrophil-like target cell to measure
patient plasma-dependent opsonophagocytosis of bacteria (Figure
S1). Plasma from premature infants carried a significantly lower
opsonophagocytic capacity than term newborns and adults for
E.coli and S.aureus (Figure 2A, B). Plasma from ELBW infants had a
lower opsonophagocytic capacity to S.epidermidis compared to
VLBW infants, term newborns and adults (Figure 2A,B). The
opsonic capacity of adult plasma to S.aureus was markedly higher
than that of newborns, suggesting the acquisition of S.aureus
opsonins during the post-natal period. In a subset of patients,
opsonophagocytosis was tested with primary neutrophils as target
phagocytes, and confirmed the defective phagocytic capacity to
E.coli, S.aureus, and S.epidermidis in ELBW observed using HL-60
cells (Figure S2).
Defective inflammatory response to bacteria in
leukocytes from premature infants
Premature infants, particularly ELBW infants, had a lower
inflammatory response to LPS, and to a lower extent to the
lipopeptide PAM3CSK4 (Figure 3A). Interestingly, term newborns
showed a significantly higher inflammatory response than control
adults. Similarly to purified bacterial agonists, the inflammatory
response to whole heat-killed bacteria (E.coli, S.aureus, S.epidermidis)
was markedly lower in ELBW infants when compared to term
newborns and adults (Figure 3B). Consistent with results obtained
with stimulation with bacterial agonists, leukocytes from term
newborns showed a stronger response than adults to heat-killed
E.coli and S.epidermidis (Figure 3B).
Markers of innate immunity correlate with birth weight
Data from 60 patients were available to correlate birth weight
and the expression of receptors of the innate immunity. A
significant correlation was found between birth weight and surface
receptor levels on phagocytes. Birth weight positively correlated
with surface neutrophil expression of MD-2 (rho 0.62, P,0.001),
CD14 (rho 0.34, P=0.009), and TLR2 (rho 0.34, P=0.009), but
not TLR4 (rho 0.048, P=0.718). Birth weight correlated with
monocyte surface expression of MD-2 (rho 0.70, P,0.001), TLR4
(rho 0.33, P=0.011), CD14 (rho 0.58, P,0.001), and TLR2 (rho
0.61, P,0.001). No correlation was found between birth weight
and CD16, HLA-DR, and white blood cell count. Furthermore,
birth weight correlated with levels of plasma-dependent opsono-
phagocytis for E.coli (rho 0.52, P,0.001), S.aureus (rho 0.55,
P=0.001), and S.epidermidis (rho 0.54, P,0.001). Finally, birth
weight also positively correlated with levels of inflammatory
cytokines in conditioned plasma from whole blood stimulated with
LPS (rho 0.66, P,0.001), PAM3CSK4 (rho 0.57, P,0.001), heat-
killed E.coli (rho 0.59, P,0.001), S.aureus (rho 0.54, P,0.001), and
S. epidermidis (rho 0.56, P,0.001).
Treatment of whole blood from premature infants with
interferon-c reverses the defect in anti-bacterial innate
immunity
Since we observed a marked defect in innate immune receptors
and activity against bacteria in circulating leukocytes from
premature infants, we tested the hypothesis that the immunomod-
ulating cytokine interferon-c may reverse this phenotype [13]. A
12 hr-course ex vivo treatment of whole blood with IFN-c restored
LPS responsiveness of circulating leukocytes from premature
infants to levels measured in control adults (11.264.5 ng/mL IL-6
in conditioned supernatants from IFN-c treated neonate leuko-
cytes stimulated with LPS vs. 16.762.8 in untreated leukocytes
from healthy adults stimulated with LPS) (Figure 4A). This was
observed for the two pro-inflammatory cytokines TNF-a and IL-6.
In contrast, the anti-inflammatory and immuno-suppressive IL-10
cytokine was decreased after IFN-c treatment when whole blood
was stimulated with LPS. Furthermore, phagocytosis of E.coli and
staphylococci by DMSO-differentiated HL-60 cells was increased
significantly when plasma was obtained in premature whole blood
treated ex vivo by IFN-c (Figure 4B). Altogether these results
suggest that IFN-c matured circulating leukocytes by increasing
the expression of receptors of the innate immunity and opsonins,
and polarized the immune response towards a Th1 response [14].
Discussion
Herein, we show that premature infants, and particularly
neonates with extremely low birth weight (ELBW), are born with
an immature innate immunity resulting in a profound defect in the
recognition and the clearance of bacteria. These defects in the
capacity to mount a proper inflammatory response and to
phagocytise bacteria are likely to account for the high incidence
of neonatal sepsis associated with extreme prematurity. Impor-
tantly, a short treatment course with the immunomodulating
cytokine IFN-c was able to enhance proinflammatory and
phagocytic responses in leukocytes from premature infants.
A low leukocyte TLRs expression in premature infants has been
suggested in other studies [9,10,11]. We show in the present work
Figure 1. TLR2, TLR4, CD14, and MD-2 surface expression of blood leukocytes and plasma soluble MD-2 activity from premature
infants, term newborns, and control adults. (A) Representative flow cytometry plot showing forward and side-scatter characteristics gating
used to identify neutrophils (R1), and monocytes (R2). (B) Surface expression of TLR4, MD-2, CD14 and TLR2 of phagocytes (neutrophils and
monocytes) from extremely low birth weight infants (ELBW, born before 28 wks of gestational age, N=18), very low birth weight infants (VLBW, born
between 28–32 wks of gestational age, N=17), term newborn (TN, N=25), and control adult (CA, N=20). In addition the expression of the Fcc
receptor CD16 on neutrophils and the major histocompatibility HLA-DR on monocytes are shown. Receptor expression was measured by flow
cytometry, and expressed as mean fluorescence index (MFI, geo mean receptor/geo mean IgG control). Errors bars are means 6 SEM, On each line, a
reference group (*) is compared to other groups and respective P value expressed using Mann-Whitney U test. (C) Plasma soluble MD-2 activity was
measured as the capacity of plasma to support TLR4-HEK293 cell activation after a 30 ng/mL LPS challenge [50]. Human recombinant soluble MD-2
(1 mg/mL) was used as a positive control. (ELBW, extremely low birth weight premature infants born before 28 wks of gestational age N=20; VLBW,
very low birth weight premature infants born between 28–32 wks of gestational age, N=20; TN, term newborns, N=20; CA, control adults, N=20).
Errors bars are means 6 SEM.
doi:10.1371/journal.pone.0032863.g001
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low in neutrophils and monocytes from extremely premature
newborns. The marked defective expression of MD-2, a key
component of the LPS receptor, may well be responsible for the
lack of innate inflammatory and immune response to bacteria
observed in premature infants [15], and hyporesponsiveness of
monocytes to LPS from premature infants [9]. Given the essential
role of MD-2 in the control of Gram-negative infections, it is a
possibility that the observed MD-2 deficiency accounts for the
propensity of premature infants to developed life-threatening E.coli
Figure 2. Phagocytosis of bacteria by newborn and adult neutrophils, and plasma opsonic activity. (A) Phagocytosis of fluorescent
E.coli, S.aureus, and S.epidermidis by neutrophils from one representative subject from each group (ELBW, extremely low birth weight premature
infants born before 28 wks of gestational age; VLBW, very low birth weight premature infants born between 28–32 wks of gestational age; TN, term
newborns; and CA, control adults). Phagocytosis was measured by flow cytometry after 10 min (red lines) and 20 min (green lines) incubation with
bacteria opsonised with autologous plasma. Neutrophils pre-incubated with the phagocytosis blocker cytochalasin D are presented with filled curves
(negative control). (B) The opsonic capacity of patient’s plasma using neutrophil-like human HL-60 cells is tested. Fluorescent E.coli, S.aureus, and
S.epidermidis were opsonised with autologous plasma and incubated 40 min with DMSO-differentiated HL-60 cells. Intracellular fluorescence
(phagocytosis of bacteria) was measured by flow cytometry and expressed as mean phagocytic index (6 SEM) of the four groups (ELBW, extremely
low birth weight premature infants born before 28 wks of gestational age N=21; VLBW, very low birth weight premature infants born between 28–
32 wks of gestational age, N=24; TN, term newborns, N=25; CA, control adults, N=20). On each line, a reference group (*) is compared to other
groups and respective P value expressed using Mann-Whitney U test.
doi:10.1371/journal.pone.0032863.g002
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that the absence of MD-2 may participate in the pathogenesis of
necrotizing enterocolitis in premature infants [18].
Phagocytosis was also severely impaired in premature infants.
Plasma-dependent opsonophagocytosis of S.aureus was found to be
low both in premature and term newborns and was only efficient
in control adults. This suggests that plasma opsonins important for
S.aureus phagocytosis appear in the postnatal period. Plasma
opsonophagocytosis of S.epidermidis was low in ELBW infants but
not in older infants. This is in accordance with epidemiological
data showing that extreme prematurity is associated with an
elevated incidence of S.epidermidis neonatal sepsis [16]. An initial
pro-inflammatory reaction is key to control bacterial infection
[19]. A marked decrease in the inflammatory response to bacteria
and bacterial agonists was principally observed in leukocytes from
ELBW infants. This may be due to the low levels of receptors for
Figure 3. Whole blood response to bacterial agonists and heat-killed bacteria. (A) Whole blood obtained from subjects of the four groups
(ELBW, extremely low birth weight premature infants born before 28 wks of gestational age, N=9; VLBW, very low birth weight premature infants
born between 28–32 wks of gestational age, N=9; TN, term newborns, N=18; CA, control adults, N=24) were stimulated 12 hrs with LPS (2.5 ng/mL)
or PAM3CSK4 (25 ng/mL). Interleukin-8 levels (mean 6 SEM) were quantified by ELISA in conditioned plasma. On each line, a reference group (*) is
compared to other groups and respective P value expressed using Mann-Whitney U test. (B) Whole blood obtained from subjects of the four groups
(ELBW, extremely low birth weight premature infants born before 28 wks of gestational age, N=9; VLBW, very low birth weight premature infants
born between 28–32 wks of gestational age, N=9; TN, term newborns, N=18; CA, control adults, N=24) were stimulated 12 hrs with heat-killed
bacteria (3.7610
6 E. coli, S. epidermidis, and 1.56610
6 S. aureus). Interleukin-6 levels (mean 6 SEM) were quantified by ELISA in conditioned plasma.
On each line, a reference group (*) is compared to other groups and respective P value expressed using Mann-Whitney U test.
doi:10.1371/journal.pone.0032863.g003
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premature infants. In contrast, term newborns displayed a robust
pro-inflammatory response, even greater than that of adult
controls. This phenomenon was also observed by others and
may be related to the lack of a proper counter-regulation by the
anti-inflammatory cytokine IL-10, and/or to a leukocyte priming
Figure 4. LPS responsiveness of leukocytes and opsonic capacity of plasma from premature infants with and without the addition
of interferon-c. (A) Whole blood from 7 extremely premature infants (born before 28 wks of gestational age) was treated ex vivo or not for 12 hrs
with interferon (IFN)-c. LPS was then added for an additional 12 hrs and IL-6, TNF-a, and IL-10 were measured (mean 6 SEM) in conditioned plasma.
(B) The plasma from whole blood obtained in seven extremely premature infants (born before 28 wks of gestational age) treated ex vivo or not with
for 12 hrs with IFN-c was incubated with fluorescent E.coli, S.aureus and S.epidermidis (opsonisation). Opsonised bacteria were then incubated with
neutrophil-like HL-60 cells for 40 min; intracellular fluorescence was measured by flow cytometry, and expressed as mean phagocytic index (6 SEM).
Statistical significance was tested with Wilcoxon matched-pairs signed rank test.
doi:10.1371/journal.pone.0032863.g004
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hyperresponsiveness observed in term newborn leukocytes is
repressed in early post-natal months, and progressively re-increase
to an adult response level within the first year of life [24]. The vast
majority of mothers who delivered premature infants were treated
with antenatal glucocorticoids in order to promote lung matura-
tion; only 3 ELBW infants were born from untreated mothers due
to emergency delivery. Both the inflammatory response and
opsonophagocytosis were similar between ELBW infants from
mothers treated or not, suggesting that antenatal steroid therapy
did not influence postnatal innate immune response (data not
shown).
Altogether, the extreme susceptibility of preterm newborns to
invasive bacterial infection may be explained by the observed
defects in both opsonophagocytosis and pro-inflammatory re-
sponses in this patient population. We have focused our work only
on selective aspects of innate immune responses, i.e. inflammation
and phagocytosis. Neutrophil chemotaxis was for example not
studied but is evidently important in the context of innate immune
defenses to pathogens, and has been shown to be defective in
newborn and premature infants [25]. This defective migration
capacity of neutrophils may also account for an elevated rate of
neonatal sepsis. Interestingly, C-X-C chemokine receptor 2
(CXCR2) surface expression was recently shown to be closely
related to TLRs mediated inflammatory response through the
modulation of phosphatidylinositol 3-kinase (PI3K) [26,27]. On
the other hand, intracellular signaling proteins in the TLR
pathway, such as MyD88 and IRF5, were also found at low levels
in premature infant leukocytes [11]. The concomitant defective
LPS responsiveness and chemotaxis of blood leukocytes from
extremely low birth weight infants raises the question of a possible
defective cross talk between TLRs and chemotaxis via the PI3K
pathway.
It seems likely that extremely premature newborns are born
with an immature innate immune system, possibly because of the
lack of physiological immune maturation happening late in
gestation, close to the term. In our study, we showed that a short
ex vivo treatment with Th1-inducing cytokine interferon-c matured
leukocytes from preterm infants. This situation is reminiscent of
that observed in critically ill patients who suffer from immunopar-
alysis or leukocyte reprogramming [19,28,29]. Phagocytes from
septic patients lose their ability to mount a proper pro-
inflammatory response to bacterial pathogens and this phenom-
enon is believed to play a significant role in the development of
secondary bacterial infections [25]. Boosting the immune system
with IFN-c or GM-CSF has become a rational strategy and was
associated with favourable outcomes in patients with sepsis
[13,30,31]. Herein, we showed that ex vivo stimulation of whole
blood from very premature infants with IFN-c increased both pro-
inflammatory response to LPS and plasma opsonophagocytosis
capacity.
We tested the opsonophagocytic activity of conditioned plasma
by incubating bacteria with conditioned supernatants from IFN-c-
treated leukocytes [32]. We found an increase in bacterial
phagocytosis. This is most likely in relation with opsonins adsorbed
by bacteria, opsonins that were produced by neonate leukocytes in
response to the IFN-c treatment. Among the possible IFN-g
inducible opsonins, we favor pentraxins (C-reactive protein,
PTX3), and soluble MD-2 [33], although this was not tested.
Since opsonised bacteria were extensively washed before given to
HL-60 cells for phagocytosis, it is unlikely that unbound soluble
factors from conditioned supernatants were transferred together
with bacteria and have influenced HL-60 phagocytic capacity.
Premature infants are known to have a ‘‘Th2’’ dominance, with
a decreased IFN-c production by NK cells, partly related to
epigenetic regulation of the IFN-c gene expression, but also due to
a decreased IL-12 and IL-18 production by antigen-presenting
cells [14,34]. Skewing the immune response toward a Th2
response appears to be an evolutionary adaptation protecting
placenta and foetus against maternal immune-mediated rejection
[35]. In the foetus, Th2 polarization is orchestrated by different
regulatory proteins, such as IL-10, prostaglandin E2, and
progesterone [36,37]. Effects of IFN-c on the immune system
are numerous, including the upregulation of TLRs expression, and
particularly TLR4 and MD-2, as well as in the stimulation of
phagocytosis [24,33,38]. Interestingly, the ex-vivo IFN-c treatment
of newborn whole blood increased leukocyte chemotaxis, as well as
bacterial and fungal killing [39,40,41]. IFN-c therapy was also
shown to reduce the occurrence of severe infections in children
with a chronic granulomatous disease [42]. We propose that our
results serve as a proof-of-concept of pharmacologically-induced
maturation of innate immunity in premature infants, similarly to
foetal lung maturation by antenatal treatment with corticosteroids
[43]. Although IFN-c therapy was not associated with significant
toxicity in children with chronic granulomatous disease [42], this
cytokine can induce fever and flu-like symptoms, which may mask
signs of sepsis in the fragile population of premature infants. In
addition, IFN-c could, at least theoretically, impair glial
differentiation, and participate in the development of periventric-
ular leukomalacia [44,45]. Another phagocyte maturating agent,
GM-CSF, was shown to reverse ex-vivo sepsis-associated monocytic
immunosuppression in adults and could be an alternative to IFN-c
[30]. GM-CSF was administered in a controlled trial in critically ill
premature infants patients performed and failed to demonstrate
protection against neonatal sepsis and did not significantly modify
the outcome [46]. The reason of the relative inefficiency of GM-
CSF in premature infants has been illustrated by the selective
impaired anti-apoptotic effect (alteration of cytochrome C release
and caspase-3 and -9 activity) of GM-CSF on newborn neutrophils
[47]. Furthermore, the absence of a prophylactic effect of GM-
CSF may have been explained by the already increased plasma
levels measured in premature infants [48].
In conclusion, we show in the present study that key innate
immune functions of phagocytes are severely impaired in
premature infants, particularly in those with extremely low birth
weight. We demonstrate that the innate immune system matures
with gestational age. Although a definite relationship between this
innate immune defect and the high incidence of neonatal sepsis in
the population of premature neonates has not been formally
established, it is tempting to relate the two phenomena. We also
show that the innate immune deficiency in extreme premature
infants can be reversed by treatment with IFN-c, opening a new
therapeutic avenue to prevent the development of bacterial
infections in premature newborns.
Materials and Methods
Patients and Samples
Ninety patients were included in the study. No patients had
sepsis or suspected chorioamionitis at the time of delivery.
Extremely low birth weight (ELBW, born before the 28
th week
of gestational age) premature infants were compared to very low
birth weight (VLBW, born between 28 and 32 wks of gestational
age) premature infants, term newborns (TN) and control adults
(CA). The study was approved by the University Hospital of
Geneva Ethics Committee and registered to ClinicalTrials.gov
(identifier: NCT00866567), and a written informed consent was
Innate Immune Response in Premature Infants
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consecutive premature infants delivered were included. Heparin-
ised blood obtained from umbilical cord was collected immediately
after delivery and processed in the laboratory within 12 hrs after
collection. Plasma was obtained by centrifugation of heparinised
whole blood and stored at 270uC. A complete blood cell count
was performed in all premature infants, and in a subset of term
newborns. Control blood from adults was obtained by venipunc-
ture and treated as newborn’s blood.
Cells and Reagents
Human HL-60 cell line was obtained from American Type
Culture Collection (ATCC, Manassas, VA) and cultured in RPMI
supplemented with 10% FCS (Amimed, Bioconcept, Basel,
Switzerland), 2 mM L-glutamine, 10 mM HEPES, 50 mg/mL
gentamicine and 50 U/mL penicillin. HL-60 cells were differen-
tiated into neutrophil-like cells with 1.2% dimethylsulfoxyde
(DMSO, Sigma, St Louis, MO) for 11 days [49]. The expression
of Fc-c receptors CD16, CD32, and CD64 in differentiated HL-60
cells was determined by flow cytometry using appropriate
antibodies (BD Biosciences Pharmigen, San Diego, CA, Figure
S1). Human embryonic kidney (HEK) 293 cells expressing human
TLR4 (TLR4-HEK293) were cultured in DMEM supplemented
with 10% FCS, 2 mM L-glutamine, 10 mM HEPES, 50 mg/mL
gentamicine and 50 U/mL penicillin [50]. S.epidermidis, S.aureus,
and E.coli were obtained from the Laboratory of Bacteriology of
our institution and originated from positive blood cultures from
premature infants with neonatal sepsis. Heat-killed S.epidermidis
were labeled with fluorescein isothiocyanate (FITC) by using
NHS-Fluorescein (Pierce, Rockford, IL) according to the manu-
facturer’s protocol and stored at 220uC.
Surface Receptors Labeling and Soluble MD-2 Activity
Leukocytes from heparinised blood were isolated from red
blood cells using a gelatin gradient [6]. Remaining red blood cells
were lysed with a 0.15 M ammonium chloride shock. Leukocytes
were resuspended in PBS containing 3% heat inactivated human
plasma (stock from a single donor). To measure receptor surface
expression, leukocytes were incubated with the following murine
antibodies: anti-huCD14 28C5 MAb (a gift from P.S. Tobias, The
Scripps Research Institute, La Jolla, USA), anti-huTLR2 T2.5
MAb (eBioscience, San Diego, CA), anti-huTLR4 15C1 MAb,
anti-huMD-2 18H10 MAb (gifts from G. Elson, NovImmune SA,
Geneva, Switzerland) and a secondary APC-labeled anti-mouse
antibody (Molecular Probes, Leiden, The Netherlands) as
described [6,50,51,52]. Polymorphonuclear neutrophil (PMN),
monocyte, and lymphocyte populations were gated according to
their forward and side-scatter characteristics, their CD16 and
HLA-DR expression, and analyzed by flow cytometry. The
presence of soluble MD-2 activity in plasma was assessed using an
assay previously described [50,51]. In brief, TLR4-HEK293 cells
were stimulated with 30 ng/mL ultrapure E.coli LCD25 LPS
(Invivogen) in the presence of patient’s plasma for 21 hours or
human recombinant soluble MD-2 (1 mg/mL) as a positive
control, as described [50,51]. The secretion of IL-8 in conditioned
supernatants was quantified by ELISA [50,51].
Measurement of Opsonophagocytosis
The capacity of patient’s plasma to enhance phagocytosis of
bacteria was performed using neutrophil-like HL-60 cells differ-
entiated for 11 days with DMSO. In a subset of patients from each
group, patients’ neutrophils were used as phagocytes. Fluorescent
E. coli and S. aureus (6610
9 bacteria/mL; BODIPY FL bioparticles;
Invitrogen), and fluorescent S. epidermidis (2.5610
9 bacteria/mL)
were incubated for 1 hr at 37uC in PBS containing 5%
decomplemented patient’s plasma (opsonization period). After
washing, plasma-opsonised fluorescent bacteria were incubated
with differentiated HL-60 or patient’s neutrophils at a bacteria-to-
cell ratio of 50:1 for E coli, 2:1 for S.aureus, and 20:1 for S.epidermidis
for 20 to 40 minutes (10 to 20 minutes with primary neutrophils)
in the same buffer as that used for the opsonisation period. Cells
were then put on ice, washed once and resuspended in Hank’s
buffered salt solution. To only quantify internalized bacteria,
extracellular fluorescence was quenched with 0.05% Trypan blue
(Invitrogen). Phagocytosis inhibition by cytochalasin D (Sigma,
30 minutes treatment before adding fluorescent bacteria) served as
a negative control [51]. The amount of phagocytosis was
quantified by the calculation of the phagocytic index (PI). PI was
defined as the geometric mean of fluorescence of gated cells (with
predefined M1 gate corresponding to 99% fluorescence of
cytochalasin D negative control) multiplied by the percentage of
positive cells [53].
Whole Blood Stimulation Assay
Fresh heparinised blood from patients was diluted 1:2 with
RPMI and incubated with ultrapure E. coli K12LCD25 LPS
(Invivogen, San Diego, CA; 2.5 ng/mL), the lipopeptide
PAM3CSK4 (Invivogen; 25 ng/mL) or with heat-killed bacteria
Blood was stimulated with various concentrations of bacteria,
ranging from 10
4 to 10
8 bacteria/mL, and results were expressed
with cytokine levels obtained with a fixed concentration of
3.7610
6 bacteria/mL for S.epidermidis and S. aureus, and
1.56610
6 for E.coli. IL-6 and IL-8 levels were measured in
conditioned supernatants by ELISA as described [6]. For each
experiment with patient’s blood, blood from an adult control was
treated in parallel (positive control).
Ex-vivo Treatment with Interferon-c
In some patients, whole blood was diluted 1:2 with RPMI and
was cultured with 50 ng/mL interferon-c (IFN-c; ImukinH,
Boehringer Ingelheim, Germany) for 12 hrs at 37uC. Diluted
blood was then stimulated with ultrapure E.coli K12LCD25 LPS
(10 ng/mL) for another 12 hrs. IL-6 levels were measured in
conditioned supernatants by ELISA, whereas TNF-a, and IL-10
were measured with the BD cytometric bead array system (BD
Biosciences). Opsonophagocytosis activity of IFN-c-conditioned
plasma was measured using differentiated HL-60 incubated with
fluorescent E.coli, S.aureus and S.epidermidis, as described above.
Bacteria were incubated with conditioned plasma, and then
extensively washed before being put together with neutrophils for
the phagocytosis assay.
Statistics
We calculated that $20 patients per groups were needed to
identify a 33% variation in measured variables with a power of
.80%, and an a error ,5%. Continuous data were expressed as
median plus interquartile range or mean 6 standard error of the
mean (SEM) when appropriate. Differences between .2 groups
were tested using the Kruskal-Wallis test before performing
pairwise comparisons using the Mann-Whitney U test. [54]
Correlations were determined using the Spearman rank correla-
tion test, and Wilcoxon matched-pairs signed rank test was applied
to analyze continuous series.
Supporting Information
Figure S1 Expression of surface receptors by neutro-
phil-like DMSO-differentiated HL-60 cells. The surface
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32863expression of Toll-like receptor (TLR4), TLR2, CD14, MD-2, and
Fcc receptors CD16, CD32, CD64 was measured by flow
cytometry using appropriate monoclonal antibodies in undiffer-
entiated HL-60 cells (light grey), and in HL-60 cells differentiated
with DMSO for 11 days (black), and compared to an isotype
control antibody (dark grey).
(TIFF)
Figure S2 Opsonic capacity of autologous plasma using
autologous neutrophils as phagocytes. Phagocytosis of
fluorescent E.coli, S.aureus, and S.epidermidis (opsonised with
autologous plasma) by neutrophils from ELBW, extremely low
birth weight premature infants born before 28 wks of gestational
age, N=8; VLBW, very low birth weight premature infants born
between 28–32 wks of gestational age, N=6; TN, term newborns,
N=8; and CA, control adults, N=13). Phagocytosis was
measured by flow cytometry after 20 min and expressed as mean
phagocytic index 6 SEM).
(TIFF)
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